A randomised controlled pilot study to assess the benefit of using Reiki to treat chronic plaque psoriasis

ISRCTN	ISRCTN63003238
DOI	https://doi.org/10.1186/ISRCTN63003238
Protocol serial number	RAP study 2007
Sponsor	South Devon Healthcare NHS Foundation Trust (UK)
Funder	Newton Abbott Hospital League of Friends (UK)

Submission date: 05/10/2007
Registration date: 19/12/2007
Last edited: 08/04/2016

Recruitment status: No longer recruiting
Overall study status: Completed
Condition category: Skin and Connective Tissue Diseases

Prospectively registered

Protocol

Statistical analysis plan

Results

Individual participant data

Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Tessa Frost
Scientific

Dermatology Department
Torbay Hospital
Lawes Bridge
Torquay
TQ2 7AA
United Kingdom

Phone	+44 1803 654 869
Email	tessa.frost@nhs.net

Study information

Primary study design	Interventional
Study design	Randomised controlled trial
Secondary study design	Randomised controlled trial
Scientific title	A randomised controlled pilot study to assess the benefit of using Reiki to treat chronic plaque psoriasis
Study acronym	RAP
Study objectives	That the use of Reiki healing treament of moderate to severe psoriasis is measurably effective and the same results are able to be reproduced by any Reiki II practitioner.
Ethics approval(s)	Ethics approval received from the Devon and Torbay Research Ethics Committee (REC) on the 4th October 2007 (ref: 07/H0202/108).
Health condition(s) or problem(s) studied	Chronic plaque psoriasis
Intervention	Arm A: conventional topical treatment (as per current local practice may include the following: emollients, vitamin D creams and ointments [calcipotriol etc.], tar preparations [Alphosyl and Exorex] and topical steroids or combinations of the above - applied twice daily as per instructions per standard practice, dependant on the topical treatment of choice) and five Reiki treatments given over a 3 month period. Arm B: five consecutive reiki treatments only over 3 months but advised to continue using moisturisers.
Intervention type	Other
Primary outcome measure(s)	1. Physical Assessment: using the Psoriasis Area and Severity Index (PASI) assessment tool, validated by photographic evidence 2. Quality of Life Assessments with Dermatology Life Quality Index (DLQI) to show to which degree the psoriasis affects the patient's normal activities 3. Psychological assessment (12-item General Health Questionnaire [GHQ12]) to show if there has been any general improvement in the quality of life, regardless of the state of psoriasis 4. Health Economics Assessment
Key secondary outcome measure(s)	1. The Healing Assessment (HA) 1.1 will identify any possible trends in psychological triggers 2. The Healing Assessment (HA) 2.1 will be used to assess the relevance of any unusual experiences during treatment and to note the areas of the body which the healer feels may require extra attention
Completion date	30/09/2009

Eligibility

Participant type(s)	Patient
Age group	Adult
Lower age limit	18 Years
Sex	All
Target sample size at registration	30
Key inclusion criteria	1. Patients who suffer from stable chronic plaque psoriasis that would be appropriate for treatment by topical agents 2. Informed consent 3. Adults aged 18 years or over, male or female
Key exclusion criteria	1. Pregnant women 2. Patients with severe disease 3. Patients with unstable psoriasis and putular psoriasis 4. Patients who have already experienced healing 5. Unable to give informed consent
Date of first enrolment	15/10/2007
Date of final enrolment	30/09/2009

Locations

Countries of recruitment

United Kingdom
England

Study participating centre

Dermatology Department

Torquay
TQ2 7AA
United Kingdom

Results and Publications

Individual participant data (IPD) Intention to share	No
IPD sharing plan summary	Not provided at time of registration
IPD sharing plan

Editorial Notes

08/04/2016: No publications found, verifying study status with principal investigator